Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Eva Muñoz Couselo, MD, PhD, Vall d’Hebrón Hospital, Barcelona, Spain, talks on clinical factors to take into consideration when treating patients with BRAF-mutant metastatic melanoma, including the stage of the disease, whether the patient has brain metastasis and the patients level of lactate dehydrogenase (LDH). This interview took place at the EADO 2022 congress.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.